on Friday increased its guidance for full-year earnings, citing strong sales of anti-inflammatory treatment Dupixent and closely-watched new drug launches.
It had previously said it expected 2023 adjusted earnings per share to grow by a "low single-digit" percentage, with an additional negative currency impact of between 5.5% and 6.5%.